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TO THE EDITOR
EPP is a rare inherited disorder in which
accumulation of free protoporphyrin
(PP) IX leads to the childhood onset
of acute photosensitivity (Puy et al.,
2010). Over 95% of EPP cases are due
to co-transmission of a loss-of-function
allele of ferrochelatase (FECH) in trans
to a common hypomorphic FECH allele
(IVS3-48C), resulting in enzymatic
activity of B35% of normal (Gouya
et al., 2006, Elder et al., 2009). We
described another type of childhood-
onset protoporphyria, X-linked prot-
oporphyria (X-linked dominant proto-
porphyria (XLDPP), MIM no. 300752),
caused by gain-of-function muta-
tions within the C-terminal region of
5-aminolevulinate synthase 2 (ALAS2),
the erythroid-specific isoform of the
first enzyme of the heme biosyn-
thetic pathway (Whatley et al., 2008).
Biochemically, XLDPP only differs from
EPP in that much of the excess PP
in erythroid cells is zinc-PP rather than
free PP.
Late-onset cases of EPP have occurred
in association with myeloproliferative
or myelodysplastic disorders (MDS;
Aplin et al., 2001, Berroeta et al.,
2007, Blagojevic et al., 2010). In some
of these cases, there has been partial
or complete loss of chromosome 18,
including the FECH locus, in the
abnormal hematopoietic clone. Defects
of chromosome 18 are frequent in
MDS, but PP-induced photosensitivity
is rare. This suggests that additional
factors affecting hematopoietic clones
are required for the expression of
myelodyplasia-associated EPP.
An 89-year-old Caucasian man devel-
oped acute painful photosensitivity
on all sun-exposed areas in the summer
of 2008. There were no other photo-
sensitivity cases in the patient’s family
(Figure 1a). Within 12 hours of sun
exposure he developed burning edema
and erythema (Figure 1b). The condition
worsened progressively, and in 2011 he
also suffered from photosensitivity in
winter. Provocative phototesting was
performed. The polychromatic minimal
erythematous dose (Dermolum UM-
Mu¨ller, Moosinning, Germany) was
normal. Simple UVA phototest
(13 J cm2, UVA-700 lamp-Waldmann,
Reichstett, France, 340–400 nm) was
positive at 24 hours for erythema.
Initially, a possible drug-associated
photosensitivity was suspected because
the patient was taking perindopril
(Coversyl, Neuilly-sur-Seine, France)
for hypertension, but cessation of peri-
ndopril resulted in no improvement. The
suspicion of porphyrin-induced photo-
sensitivity was confirmed by porphyrin
measurements, establishing a diagnosis
of EPP (Table 1). The PP levels in
erythrocytes correlated with the clinical
exacerbation of photosensitivity in
2011. A mild macrocytic anemia in
the context of late-onset protoporphyria
led to bone marrow aspiration in April
2010. It showed dyserythropoiesis in a
few erythroblasts without obvious mye-
lodysplastic changes. In 2011, the
macrocytic anemia progressed without
evidence of folates or vitamin deficiency
(Table 1). Another bone marrow aspirate
showed karyorrhexis in o10% of ery-
throblasts (Supplementary Figure S1).
There was no excess of myeloblasts.
Molecular and enzymatic studies
including FECH and ALAS2 DNA
sequencing and karyotyping on the
marrow aspirate were performed. Both
FECH activity in lymphocytes and
FECH gene sequencing were normal.
Karyotyping revealed no abnormalities
of chromosome 18. Collectively, these
findings demonstrate that PP accumula-
tion was not caused by FECH defi-
ciency. These data strongly suggested
late-onset XLDPP. A nonsense ALAS2
mutation (c.1642C4T [p.Q548X] result-
ing in a 39-amino-acid, truncated pro-
tein, and to our knowledge previously
unreported, was identified in DNA
extracted from peripheral blood
(Figure 1c). The mutation was found in
some alleles but not others, strongly
suggesting somatic mosaicism in the
bone marrow. The mutated allele was
predominant in DNA extracted from
blood but was absent in hair bulbs
(Figure 1c). The pedigree data showed
that no ALAS2 genomic mutations were
found in the one daughter who was
investigated. Cytogenetic analysis of
the marrow aspirate was normal in
2010, but in 2011 a 20q deletion was
found in 20% of cells, suggesting clonal
evolution of the hematological disease.
The del(20q) is not included in the list of
recurring chromosomal abnormalities
considered as presumptive evidence of
MDS for the World Health Organization
(Vardiman et al., 2009), but could be an
early cytogenetic event in the context of
myelodysplasia (Braun et al., 2011). The
progressive macrocytic anemia, the
dyserythropoiesis, the karyorrhexis, and
the 20q deletion were consistent with
evolution into refractory anemia. The
genotyping and pedigree studies were
conducted in accordance with the
ethical principles of the World Medical
Association Declaration of Helsinki
for medical research involving human
subjects, plus its subsequent amend-
ments; all available relatives provided
their written informed consent.
Only 12 patients have been described
in whom EPP developed after the age of
40 years. In all cases, clinical symptoms
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were associated with MDS. Most of
these patients have complete or partial
deletions of chromosome 18 in
hematopoietic cells responsible for loss
of FECH alleles. We present here a case
of late-onset XLDPP, which to our
knowledge is previously unreported
and clinically indistinguishable from
late-onset EPP. The high percentage of
Patient
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*
Figure 1. Pedigree, clinical presentation, and C-terminal ALAS2 mutation in a late-onset protoporphyric patient. (a) ALAS2 (5-aminolevulinate synthase 2)
mutation in the family of the late-onset protoporphyric patient. Pedigree of the family with an ALAS2 mutation (X-linked allele). Surprisingly, we noted the absence
of mutation transmission from the father to the one daughter who was investigated (*). (b) Clinical presentation of a late-onset X-linked dominant protoporphyria
case: lesions of photosensitivity. Edema and erythema developed immediately after exposure to sunlight. Chronic lesions, such as thickening of the skin on hands
and face, were visible; the patient consented to his image being used. (c) C-terminal mutation in ALAS2. Sequence analysis of genomic DNA extracted from
peripheral blood and hair bulbs. The c.1642C4T (p.Q548X) mutation was identified in the X-chromosome in the patient. The percentage of mutated allele was
determined by PeakPicker software: http://genomequebec.mcgill.ca/EST-HapMap (Ge et al., 2005).
Table 1. Biological data of the late-onset XLDPP patient
April (2010) February (2011) September (2011)
PP in red blood cells (mmol l1 red blood cells; N:o1.9) 22.3 48.4 23.4
Free/ZnPP (%ZnPP) 45 52 NA
Total porphyrins in plasma (nmol l 1; N:o20.0) 51 77 NA
Fluorescence emission peak (in nm) 634 634 NA
Total porphyrins in urine (nmol mmol 1 creatinine; N: o30) 10 NA NA
Total porphyrins in stool (nmol g1 of dry weight; N: o200) 560 750 NA
% PP (N: 70–75%) 98 99 NA
Fech enzyme activity (nmol mg 1 protein per hour; N: 43.5) 5.2 NA NA
Hb (N:13–17g dl1) 10.5 9.0 7.9
MCV (N: 80–100 fl) 100 105 110
MCH (N: 27–32 pg) 34.1 38.4 39.2
White cell count (N: 4–10 109 per l) 4.99 5.22 4.23
Platelet count (N: 150–450 109 per l ) 123 132 129
Folates (N: 45.38 ng l1) 3.43 5.48 5.82
B12 vitamin 210–920 pg ml1 200 586 572
g-GT (N:o60 UI l1) 61 867 176
Total bilirubin (N: 2–21mmol l1) 28 32 22
ALP (N: 100–200 UI l1) 221 320 210
AST (N: 3–35 UI l 1) 34 32 30
ALT (N: 3–45 UI l 1) 10 20 29
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; MCH, MC hemoglobin; MCV,
mean corpuscular volume; NA, not available; PP, protoporphyrin; ZnPP, zinc PP; g-GT, g-glutamyl transferase.
Porphyrin measurements were performed according to the European Porphyria Network guidelines and quality-control schemes (http://www.porphyria-
europe.org).
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zinc-PP led us to suspect XLDPP, which
was confirmed by ALAS2 sequencing.
The presence of the X-linked ALAS2
mutation in the blood of a man with a
normal marrow karyotype, the absence
of transmission of the mutation to his
daughter, and the absence of the muta-
tion in the DNA from his hair bulbs
strongly supports our conclusion that a
somatic hematopoietic mosaicism was
present. Late-onset XLDPP was revealed
by expansion of the abnormal clone and
by the dyserythropoiesis secondary to an
emerging MDS as already described in
other X-chromosome genes such as
ATRX gene in a-thalassemia MDS
(Gibbons et al., 2003).
Somatic mosaicism in erythroid cells
may account for the late presentation
and for the mild severity. In adults
whose disease became manifest in
childhood, XLDPP leads to the produc-
tion of PP in sufficient quantities to
cause severe liver damage (Puy et al.,
2010). In our patient, compared with
most XLDPP patients, late onset of
XLDPP was associated with gallstones
and mild cholestasis without cytolysis
(Table 1). These relatively mild symp-
toms compared with some of the other
XLDPP patients may be related to both
its late onset and the acquired hemato-
poietic mosaicism. Two frameshift ALAS2
mutations in the C-terminal region have
been identified in XLDPP families
(Whatley et al., 2008). The p.Q548X
mutation found here is predicted to
result in the deletion of the C-terminal
region, resulting in a marked increase in
ALAS2 activity as shown in prokaryotic
expression studies (data not shown).
In conclusion, we demonstrate that
late-onset photosensitivity can be
caused by XLDPP, and that both EPP
and XLDPP should be considered
when adverse reactions to sunlight
occur in the elderly. Analysis of ALAS2
alleles in marrow DNA would seem
worthwhile in patients with late-onset
photosensitivity associated with high PP
levels in the absence of FECH deletions
or mutations.
CONFLICT OF INTEREST
The authors state no conflict interest.
ACKNOWLEDGMENTS
We thank the patient and his family for their
participation in the study; Sylvie Simonin, Anne
Marie Robreau Fraolini, and Ce´cile Demur for their
excellent laboratory assistance; and Je´roˆme
Lamoril and Caroline Kannengiesser for their valu-
able advice. The genotyping and pedigree studies
were conducted in accordance with the ethical
principles of the World Medical Association
Declaration of Helsinki for medical research invol-
ving human subjects, plus its subsequent amend-
ments; all available relatives provided their
informed consent.
Cristina Bulai Livideanu1,6,
Sarah Ducamp2,3,6, Laurence Lamant4,
Laurent Gouya2,3, Odile B. Rauzy5,
Jean C. Deybach2,3, Carle Paul1,
Herve´ Puy2,3 and Marie C. Marguery1
1Paul Sabatier University and Department of
Dermatology, Larrey Hospital, Toulouse,
France; 2Centre Franc¸ais des Porphyries,
Hoˆpital Louis Mourier, AP-HP, Colombes,
France; 3INSERM Unite´ 773, Centre de
Recherches Biome´dicales Bichat-Beaujon,
Universite´ Paris Diderot, Sorbonne Paris Cite´,
Site Bichat, Paris, France; 4Paul Sabatier
University and Department of Pathology,
Purpan Hospital, Toulouse, France and 5Paul
Sabatier University and Department of
Medicine and Clinical Immunology, Purpan
Hospital, Toulouse, France
E-mail. herve.puy@bch.aphp.fr
6These authors contributed equally to this work.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Aplin C, Whatley SD, Thompson P et al. (2001)
Late-onset erythropoietic porphyria caused by
a chromosome 18q deletion in erythroid cells.
J Invest Dermatol 117:1647–9
Berroeta L, Man I, Goudie DR et al. (2007) Late
presentation of erythropoietic protoporphyria:
case report and genetic analysis of family
members. Br J Dermatol 157:1030–1
Blagojevic D, Schenk T, Haas O et al. (2010)
Acquired erythropoietic protoporphyria. Ann
Hematol 89:743–4
Braun T, de Botton S, Taksin AL et al. (2011)
Characteristics and outcome of myelodysplas-
tic syndromes (MDS) with isolated 20q
deletion: a report on 62 cases. Leuk Res
35:863–7
Elder GH, Gouya L, Whatley SD et al. (2009) The
molecular genetics of erythropoietic protopor-
phyria. Cell Mol Biol 55:118–26
Ge B, Gurd S, Gaudin T et al. (2005) Survey of
allelic expression using EST mining. Genome
Res 15:1584–91
Gibbons RJ, Pellagatti A, Garrick D et al. (2003)
Identification of acquired somatic mutations
in the gene encoding chromatin-remodeling
factor ATRX in the alpha-thalassemia myelo-
dysplasia syndrome (ATMDS). Nat Genet
34:446–9
Gouya L, Martin-Schmitt C, Robreau AM et al.
(2006) Contribution of a common single-
nucleotide polymorphism to the genetic pre-
disposition for erythropoietic protoporphyria.
Am J Hum Genet 78:2–14
Puy H, Gouya L, Deybach JC (2010) Porphyrias.
Lancet 375:924–37
Vardiman JW, Thiele J, Arber DA et al. (2009) The
2008 revision of the World Health Organiza-
tion (WHO) classification of myeloid neo-
plasms and acute leukemia: rationale and
important changes. Blood 114:937–51
Whatley SD, Ducamp S, Gouya L et al. (2008)
C-terminal deletions in the ALAS2 gene lead
to gain of function and cause X-linked domi-
nant protoporphyria without anemia or iron
overload. Am J Hum Genet 83:408–14
CB Livideanu et al.
Late-Onset X-Linked Dominant Protoporphyria
1690 Journal of Investigative Dermatology (2013), Volume 133
